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Abstract
Objective: To evaluate the effect of topical betamethasone eye drops on 
postoperative haze among patients undergoing corneal collagen cross-
linking (CXL).
Patients and Methods: Patients with mild to moderate keratoconus, 
aged 18 to 30 years, who were a candidate for CXL treatment and had 
the evidence of disease progression based on topographic findings 
entered the present study. One eye of each patient randomly received 
betamethasone and topical antibiotics after CXL and the other eye 
received topical antibiotics and placebo in place of betamethasone. The 
eyes were compared regarding BCVA, UCVA, refraction, keratometric 
and pachymetric findings using Pentacam, as well as changes of corneal 
haze using confocal microscopy, before CXL as well as one month and 
six months after CXL. 
Results: There was no difference in BCVA, UCVA, refraction, 
keratometric and pachymetric findings between the two groups before 
and six months after surgery. Based on confocal findings, the difference 
in light reflectance intensity between the case and control groups was 
statistically significant in anterior (P = 0.021) and posterior (P = 0.017) 
corneal stroma one month postoperatively, indicating higher haze in the 
placebo group. This difference was also statistically significant in anterior 
(P = 0.001) mid (P = 0.002) and posterior (P = 0.002) stroma six months 
postoperatively. 
Conclusion: Betamethasone had no effect on visual acuity, refraction, 
keratometric and pachymetric findings six months after CXL. It reduced 
corneal haze in both the first and the sixth months postoperatively. 
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Introduction
Keratoconus is a bilateral, non-inflammatory, 
progressive disease characterized by thinning 
of the cornea, irregular astigmatism and 
decreased vision 1. The incidence of the 
disease is one in 2,000 and seems to be higher 
in Asian countries 2,3. Although the exact 
cause of keratoconus is not known, gradual 
biomechanical weakening of the cornea 
secondary to corneal collagen structural 
changes, extracellular matrix changes, and 
apoptosis have been suggested as the probable 
mechanisms 4-6. Involvement of patients with 
keratoconus in the second decade of life has a 
significant negative impact on their quality of 
life 7. Various treatments have been proposed to 
control the progress of the disease and improve 
the patients’ vision, including the use of hard 
contact lenses, corneal inserts and corneal 
transplant surgery 8,9. A relatively new method 
of treatment is corneal collagen cross-linking 
(CXL). CXL which was introduced in 2003 by 
Wollensak et al., 10 modifies the mechanical 
properties of the cornea by using riboflavin and 
UV rays to create covalent bonds in the corneal 
stroma and increase the number of collagen 
bands between the strands 11. This technique 
has been shown to affect corneal ectasia and 
to stop or even reverse its progression 12,13. 
However, as with other surgical procedures, 
this treatment may cause some short or long 
term complications, such as corneal haze, 
corneal scar, endothelial destruction, treatment 
failure, sterile infiltration, and reactivation of 
herpes infection 7,14. 
Topical treatments are used after 
many eye surgeries to relieve pain and 
inflammation, and to reduce the chance of 
potential complications. The use of topical 
corticosteroid eye drops is effective in 
controlling anterior segment inflammation by 
reducing cell infiltration, capillary dilatation, 
fibroblast proliferation, collagen deposition, 
and scarring 15. Corticosteroid eye drops have 
also been shown to be useful in reducing post 
surgical haze in refractive surgical procedures 
like photorefractive keratectomy (PRK) 16,17. 
Traditionally corticosteroid eye drops have 
been used to reduce postoperative haze in 
patients undergoing CXL, but in our search of 
English literature we did not find any previous 
studies evaluating its effect on post CXL haze. 
The present study was performed to evaluate 
the effect of topical betamethasone eye 
drops on postoperative haze among patients 
undergoing corneal collagen cross-linking 
(CXL).
Patients and Methods
This randomized, double blind, placebo 
controlled clinical trial included keratoconus 
patients referred to Torfeh Eye Hospital 
and Imam Hossein Medical Center, Tehran, 
Iran. The study was approved by the ethics 
committee of Shahid Beheshti University 
of Medical Sciences and all patients gave 
written consent before entering the study. 
The inclusion criteria were proven mild and 
moderate keratoconus with Kmax of less 
than 55 diopters, age of 18 to 30 years, BCVA 
of 8/10 or worse, topographic evidence of 
keratoconus progression such as an increase of 
more than 1 diopter in maximum keratometry 
or manifest cylinder or an increase of more than 
0.5 diopter in spherical refraction over the past 
year, and corneal thickness of at least 400 μm. 
Patients with a corneal thickness of less 
than 400 μm, any history of eye surgery, 
ocular inflammation, poor epithelium repair, 
infection and herpetic keratitis, severe corneal 
scarring or opacity, neurotrophic keratopathy 
and severe dry eye where excluded from 
the present study. Also those patients with a 
history of systemic disease such as diabetes 
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and autoimmune diseases, recent contact 
lens use in the past 6 weeks, and pregnancy 
were excluded from the study. Patients who 
were currently using corticosteroids or had 
used corticosteroids in last six months for any 
medical condition were also excluded. 
In the present study the right and left eye 
of the same patients randomly received 
either betamethasone eye drops 0.1 % 
(Pharmaceutical Distribution Company of 
Iran) as drug or Sno Tears 1.4 % eye drops 
(Bausch & Lomb, United Kingdom) as 
placebo. The drug and placebo were labeled 
in similar bottles by someone other than the 
project associates based on a randomization 
table. 
In the pre-CXL examination, the visual acuity 
of patients (UCVA and BSCVA) was assessed 
using the visual acuity chart recommended 
by the Early Treatment Diabetic Retinopathy 
Study (ETDRS) and recorded as the logarithm 
of minimal angle of resolution (LogMAR). 
Refraction, slit lamp and fundoscopy 
exams were performed for all patients and 
intraocular pressure was measured using 
Goldman tonometry. Corneal topographic 
and pachymetry parameters were measured 
and recorded using a Pentacam device. Also a 
confocal scan of the cornea was performed to 
evaluate the corneal haze.
CXL surgery 
After receiving a local anesthetic drop (0.5 % 
tetracaine) the central corneal epithelium was 
mechanically removed (8-9 mm) in sterile 
conditions and riboflavin 0.1 % eye drop 
was applied every 5 minutes for 30 minutes 
before receiving UVA radiation.  Then, the 
UVA (mean wave length 365 ± 10 nm, 9 mW 
/ cm 2) was delivered for 10 minutes from a 5 
cm distance using a Schwind CXL-365 Vario 
system (SCHWIND eye-tech-solutions GmbH 
& Co., Kleinostheim, Germany). During the 
UVA radiation riboflavin 0.1 % eye drop was 
applied every 2.5 minutes. After completion 
of radiation exposure patients received topical 
antibiotics (0.5 % chloramphenicol), and 
extended-wear lenses were applied. The same 
procedure was repeated for both eyes.
Post surgical treatment and exams
At this stage, two identical bottles containing 
either betamethasone or placebo, which were 
randomly assigned for the right or left eye 
based on a randomization table, were given 
to the patient by a non-physician. In this way 
patients and the physician were unaware of 
which eye is receiving the drug or the placebo. 
These eye drops were used by patients for 
25 days post surgery as follow: first 5 days 
every 4 hours, second 5 days every 6 hours, 
third 5 days every 8 hours, fourth 5 days every 
12 hours, and fifth 5 days, every 24 hours. 
All patients also received topical antibiotic 
(Chloramphenicol) every 8 hours in both eyes 
until one day after removal of the dressing lens. 
Artelac Advanced Eye Drop (UK by Bausch & 
Lomb, UK) was also used as needed.
All patients underwent slit lamp exam one 
day after surgery and were re-examined 3 
or 4 days after surgery. These exams were 
repeated weekly for the first month, every 
two weeks for the second month and then 
monthly from the third to the sixth month. 
In these exams patients were monitored for 
possible complications. Visual acuity (UCVA, 
BCVA), corneal topographic and pachymetry 
parameters as well as refraction were also 
assessed in the first and sixth months post 
surgery. Corneal haze was assessed and 
recorded in the first and sixth months using 
confocal microscopy.
In all postoperative exams close attention was 
given to identify possible complications of 
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not receiving betamethasone including severe 
corneal haze. If this occurred patients would 
be dropped from the study and treated for haze.
Sample size calculation and statistical methods
The sample size was calculated as 42 eyes in 
each group to detect a 10 percent difference in 
haze formation between the case and control 
groups with a type I error of 5 % and power 
of 90 %. The data was described as mean, 
standard deviation, median, range, frequency 
and percentage. Baseline values between 
the two groups were compared using paired 
sample t-test. Post operation values were 
compared when adjusted for the baseline 
using generalized estimating equation (GEE). 
SPSS version 20 (Armonk, NY: IBM Corp.) 
statistical program was used to analyze the 
results. P values less than 0.05 were considered 
statistically significant.
Results
A total of 43 patients with keratoconus who 
met the inclusion and exclusion criteria were 
included in the present study, of whom 23 were 
male (53.3 %) and 20 were female (46.5 %), 
with a mean age of 25 ± 4 years (Table 1).
According to the randomization table, 24 
patients (55.8 %) used topical betamethasone 
after CXL in the right eye and placebo 
(artificial tears) in the left eye, and 19 patients 
(44.2 %) used topical betamethasone in the 
left eye and placebo (artificial tears) in the 
right eye (Table 1).
The mean uncorrected visual acuity (UCVA) 
in betamethasone treated and placebo treated 
eyes prior to CXL treatment was 0.71 ± 0.41 
LogMAR and 0.74 ± 0.4 LogMAR respectively, 
indicating no significant difference between 
the two groups (Table 2). In the first month 
after CXL treatment, the UCVA in the 
betamethasone group and the placebo 
recipient group was 0.8 ± 0.43 LogMAR and 
LogMAR 0.79 ± 0.41 respectively, indicating 
no significant difference (Table 2). Also no 
significant difference in UCVA was observed 
in the third and sixth months (Table 2). 
Similarly according to table 2 there was no 
statistically significant difference between 
the case and control groups regarding the 
BCVA, sphere, cylinder, spherical equivalent 
(SE), Kmin, Kmax, KImean and pachymetry 
readings either before treatment or 1 and 6 
months after treatment.
The amount of light reflectance intensity at 
three levels of anterior, middle and posterior 
stroma according to confocal scan findings, as 
an indicator of haze, are shown in table 3.
As can be observed in table 3 there was no 
statistically significant presurgical difference 
of light reflectance intensity between the case 
and control groups in any level of corneal 
stroma.
One month postoperatively the difference in 
light reflectance intensity between the case and 
control groups was statistically significant in 
anterior (P = 0.021) and posterior (P = 0.017) 
corneal stroma indicating higher haze in the 
Table 1: The demographic findings of 
patients entering the study
Parameter  Value
Age Mean ± SD 25 ± 4
Median 
(range)
25 (18 to 
30)
Sex M 23 (53.5 %)
F 20 (46.5 %)
Eye receiving 
betamethasone
OD 24 (55.8 %)
 OS 19 (44.2 %)
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placebo group. Six months postoperatively 
the difference in light reflectance intensity 
between the case and control groups was 
statistically significant in anterior (P = 0.001) 
mid (P = 0.002) and posterior (P = 0.002) 
corneal stroma, also indicating higher haze in 
the placebo group. 
Discussion
In the present study, the effect of betamethasone 
on postsurgical haze in eyes with mild to 
moderate keratoconus was evaluated.
The average age of patients included in this 
study was 25 years, which is in line with 
the results of other epidemiological studies 
Table 2: The comparison of visual findings before treatment as well as one and six 
months after treatment between the case and control groups
Parameter  Time Group Difference 
Mean ± SD
95% CI P value*
Betamethasone  Placebo Lower Upper
UCVA (LogMAR) Before 0.71 ± 0.41 0.74 ± 0.4 - 0.03 ± 0.29 - 0.12 0.06 0.505 
1 month 0.8 ± 0.43 0.79 ± 0.41 0 ± 0.29 - 0.09 0.10 0.966
6 months 0.73 ± 0.41 0.75 ± 0.42 - 0.02 ± 0.28 - 0.11 0.07 0.631
BCVA (LogMAR) Before 0.25 ± 0.16 0.24 ± 0.18 0 ± 0.21 - 0.06 0.07 0.882
1 month 0.28 ± 0.2 0.26 ± 0.22 0.01 ± 0.24 - 0.06 0.09 0.705
6 months 0.22 ± 0.16 0.22 ± 0.19 0 ± 0.2 - 0.06 0.07 0.934
Sphere Before - 2.17 ± 1.93 - 1.98 ± 1.74 - 0.19 ± 1.79 - 0.75 0.36 0.491
1 month - 2.48 ± 2.01 - 2.09 ± 1.72 - 0.39 ± 1.54 - 0.88 0.10 0.119
6 months - 2.48 ± 1.99 - 2.11 ± 1.73 - 0.38 ± 1.5 - 0.85 0.10 0.121
Cylinder Before - 2.18 ± 1.41 - 2.47 ± 1.58 0.29 ± 1.65 - 0.22 0.80 0.257
1 month - 2.13 ± 1.44 - 2.54 ± 1.77 0.41 ± 1.39 - 0.03 0.86 0.068
6 months - 2.26 ± 1.48 - 2.6 ± 1.77 0.34 ± 1.53 - 0.15 0.83 0.164
SE Before - 3.26 ± 2.08 - 3.22 ± 2.13 - 0.05 ± 2.17 - 0.72 0.63 0.892
1 month - 3.55 ± 2.11 - 3.37 ± 2.07 - 0.18 ± 1.81 - 0.76 0.40 0.530
6 months - 3.61 ± 2.06 - 3.41 ± 2.06 - 0.2 ± 1.84 - 0.79 0.39 0.489
Kmin Before 44.3 ± 2.8 44.3 ± 2.5 0.03 ± 2.46 - 0.73 0.79 0.934
1 month 44.4 ± 2.8 44.2 ± 2.5 0.18 ± 2.35 - 0.57 0.93 0.630
6 months 44.3 ± 2.8 44.1 ± 2.4 0.18 ± 2.33 - 0.56 0.93 0.622
Kmax Before 47.6 ± 3.4 47.4 ± 3.3 0.16 ± 3.33 - 0.87 1.18 0.755
1 month 47.6 ± 3.5 47.4 ± 3.2 0.15 ± 2.97 - 0.80 1.10 0.747
6 months 47.5 ± 3.5 47.4 ± 3.2 0.15 ± 2.98 - 0.80 1.10 0.752
Kmean Before 45.8 ± 2.9 45.7 ± 2.7 0.11 ± 2.64 - 0.70 0.92 0.786
1 month 45.9 ± 2.9 45.7 ± 2.6 0.18 ± 2.5 - 0.61 0.98 0.642
6 months 45.8 ± 3 45.6 ± 2.6 0.21 ± 2.53 - 0.60 1.02 0.602
Pachymetry Before 474 ± 74 486 ± 42 - 11.21 ± 84.07 - 37.08 14.66 0.387
1 month 480 ± 34 476 ± 43 3.1 ± 31.56 - 6.99 13.19 0.538
6 months 484 ± 35 482 ± 42 1.65 ± 30.43 - 8.08 11.38 0.734
Before: Before surgery; 1 month: One month after CXL; 6 months: Six months after CXL
*Based on paired sample t-test when comparing baseline values between two groups and generalized estimating 
equation when comparing post operation values (GEE)
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regarding the age of keratoconus, indicating 
the highest prevalence of disease in the third 
decade of life 8. The percentage of male patients 
enrolled in the present study (53.5 %) was 
slightly higher than female patients (46.5 %), 
although this difference was not statistically 
significant.
In our study, the increase in BCVA was 
0.03 ± 0.06 and 0.02 ± 0.06 in eyes receiving 
betamethasone and placebo respectively, 
indicating no difference between the two groups 
regarding the improvement in BCVA. Wisse 
et al.,18 in their study aimed at investigating 
the visual acuity predictors after receiving 
CXL treatment reported a mean improvement 
in BCVA of 0.13 LogMAR after one year of 
follow up. This improvement in another study 
by Lamy et al., 19  with a two years follow up 
was 0.16 LogMAR. The difference in the rate 
of patients’ vision improvement in this study 
compared to other studies is probably due to 
the shorter follow-up period and indicates the 
need for further follow-up.
In the present study based on confocal findings, 
a significant increase in light reflectance 
intensity indicating increased haze was 
observed in the first month after CXL in both 
betamethasone and placebo groups and then 
the haze subsided at 6 months postoperatively. 
Similarly in a study by Greenstein et al., 20 
corneal opacity showed an increase at one 
month after CXL and then decreased after 6 
months. We observed the highest opacity at 
the anterior stroma followed by the posterior 
and mid stromal levels.
In the present study the difference in light 
reflectance intensity between the case and 
control groups was statistically significant 
in anterior and posterior corneal stroma one 
month postoperatively, indicating higher 
haze in the placebo group. This difference 
was also statistically significant in anterior, 
mid and posterior corneal stroma six months 
postoperatively. These findings indicate the 
usefulness of betamethasone eye drops in 
reducing the haze formation after CXL surgery 
in short term. We recommend similar studies 
with longer follow up to find if the effect of 
Table 3: Light reflectance intensity at three levels of anterior, middle and posterior 
stroma according to confocal scan findings in the case and control groups
Parameter Time Group      P value*
Betamethasone Placebo
Anterior stroma Before CXL 65.8 ± 13 69.7 ± 20.1 0.178
1 month after CXL 118.7 ± 31.3 140.7 ± 63.8 0.021
6 months after CXL 66.3 ± 12.2 78.6 ± 23.6 0.001
Mid stroma Before CXL 45.8 ± 8.3 46.3 ± 6.8 0.564
1 month after CXL 55.7 ± 16.6 60.7 ± 23.7 0.073
6 months after CXL 46.6 ± 7.3 50.6 ± 9.6 0.002
Posterior stroma Before CXL 69 ± 7.6 70.2 ± 7.4 0.282
1 month after CXL 76.6 ± 14.9 81.5 ± 18.5 0.017
6 months after CXL 68.5 ± 8.2 73.2 ± 9.7 0.002
* Based on paired sample t-test when comparing baseline values between two groups and generalized 
estimating equation (GEE) when comparing post operation values
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betamethasone in reducing haze after CXL is 
still significant after longer follow up periods.
To our knowledge the present study is the first 
study evaluating the effect of betamethasone 
eye drops in reducing the post CXL haze 
formation in English literature. One of the 
strengths of the present study was evaluating 
the haze based on confocal microscopy, which 
is a quantitative and accurate method, instead 
of simple slit lamp examination of the cornea 
by the examiner. This enabled a more accurate 
comparison of haze between the case and 
control groups. 
Conclusion
Betamethasone had no effect on visual acuity, 
refraction, keratometric and pachymetric 
findings six months after CXL. It reduced 








1. Vazirani J, Basu S. Keratoconus: current 
perspectives. Clin Ophthalmol. 2013;7:2019-30. 
2. Gomes JA, Tan D, Rapuano CJ, Belin MW, 
Ambrósio Jr R, Guell JL, et al. Global consensus 
on keratoconus and ectatic diseases. Cornea. 
2015;34(4):359-69.
3. Kok YO, Tan GF, Loon SC.Review: keratoconus in 
Asia. Cornea. 2012;31(5):581-93.
4. Radner W, Zehetmayer M, Skorpik C, Mallinger 
R. Altered organization of collagen in the apex 
of keratoconus corneas. Ophthalmic research. 
1998;30(5):327-32.
5. Daxer A, Fratz P. Collagen fibril orientation 
in the human corneal stroma and its implication 
in keratoconus. Invest Ophthalmol Vis Sci. 
1997;38(1):121-9.
6. Olivares Jiménez JL, Guerrero Jurado JC, 
Bermudez Rodriguez FJ, Serrano Laborda D. 
Keratoconus: age of onset and natural history. Optom 
Vis Sci. 1997;74(3):147-51.
7. Razmjoo H, Rahimi B, Kharraji M, Koosha N, 
Peyman A. Corneal haze and visual outcome after 
collagen crosslinking for keratoconus: A comparison 
between total epithelium off and partial epithelial 
removal methods. Adv Biomed Res. 2014;3:221. 
8. Colin J, Velou S. Current surgical options for 
keratoconus. J Cataract Refract Surg. 2003;29(2):379-
86.
9. Samaras KE, Lake DB. Corneal collagen cross 
linking (CXL): a review. Int Ophthalmol Clin. 
2010;50(3):89-100.
10. Wollensak G, Spoerl E, Seiler T. Riboflavin/
ultraviolet-a-induced collagen crosslinking for 
the treatment of keratoconus. Am J Ophthalmol. 
2003;135(5):620-7.
11. Abdolahian M, Zolghadr GH. Corneal Collagen 
Crosslinking for Treatment of Keratoconus. Journal 
of Ophthalmic and Optometric Sciences. 2017;1(4):8-
14.
12. Wollensak G. Crosslinking treatment of 
progressive keratoconus: new hope. Curr Opin 
Ophthalmol. 2006;17(4):356-60.
13. Nassiri N, Azemati A. The Use of Corneal Cross-
linking in Treatment of Progressive Keratoconus: 
a Review. Journal of Ophthalmic and Optometric 
Sciences. 2017;1(4):15-21.
14. Dhawan S, Rao K, Natrajan S. Complications 
of corneal collagen cross-linking. J Ophthalmol. 
2011;2011:869015. 
15. Pleyer U, Ursell PG, Rama P. Intraocular pressure 
effects of common topical steroids for post-cataract 
Nassiri et al. The Effect of Topical Betamethasone Eye Drops
Journal of Ophthalmic and Optometric Sciences. Volume 2, Number 2, Spring 2018.
This work is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
24
inflammation: are they all the same?. Ophthalmol 
Ther. 2013;2(2):55-72. 
16. Nien CJ, Flynn KJ, Chang M, Brown D, Jester 
JV. Reducing peak corneal haze after photorefractive 
keratectomy in rabbits: prednisolone acetate 1.00% 
versus cyclosporine A 0.05%. J Cataract Refract Surg. 
2011;37(5):937-44. 
17. Vetrugno M, Maino A, Quaranta GM, Cardia L. 
The effect of early steroid treatment after PRK on 
clinical and refractive outcomes. Acta Ophthalmol 
Scand. 2001;79(1):23-7.
18. Wisse RP, Godefrooij DA, Soeters N, Imhof SM, 
Van der Lelij A. A multivariate analysis and statistical 
model for predicting visual acuity and keratometry 
one year after cross-linking for keratoconus. Am J 
Ophthalmol. 2014;157(3):519-25.
19. Lamy R, Netto CF, Reis RG, Procopio B, Porco 
TC, Stewart JM, et al. Effects of corneal cross-linking 
on contrast sensitivity, visual acuity, and corneal 
topography in patients with keratoconus. Cornea. 
2013;32(5):591-6.
20. Greenstein SA, Fry KL, Bhatt J, Hersh PS. Natural 
history of corneal haze after collagen crosslinking for 
keratoconus and corneal ectasia: Scheimpflug and 
biomicroscopic analysis. J Cataract Refract Surg. 
2010;36(12):2105-14.
Footnotes and Financial Disclosures
Conflicts of Interest:
The authors have no conflict of interest with 
the subject matter of the present manuscript. 
Nassiri et al.The Effect of Topical Betamethasone Eye Drops
